Kura Oncology (KURA) and its partner Kyowa Kirin said Thursday that updated clinical data from their phase 1a/1b trial of ziftomenib combined with standards of care showed that 92% of 71 response-evaluable patients with acute myeloid leukemia achieved a composite complete remission and 80% achieved a complete remission.

The study evaluated ziftomenib plus cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements.

The company said phase 3 studies further evaluating ziftomenib-based combination therapies are expected to start in H2.

Kura Oncology's shares were up 3.8% in recent premarket activity Thursday.